Get the Stockscreener App
1.92
1.03%
-0.02
After Hours:
1.91
-0.01
-0.52%
Traws Pharma Inc stock is traded at $1.92, with a volume of 134.80K.
It is down -1.03% in the last 24 hours and up +51.18% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$1.94
Open:
$1.94
24h Volume:
134.80K
Relative Volume:
0.32
Market Cap:
$15.34M
Revenue:
$2.90M
Net Income/Loss:
$87.91M
P/E Ratio:
0.123
EPS:
15.6103
Net Cash Flow:
$-26.93M
1W Performance:
+11.63%
1M Performance:
+51.18%
6M Performance:
+17.79%
1Y Performance:
-72.13%
1-Day Range:
$1.8601
$2.08
1-Week Range:
$1.79
$2.31
52-Week Range:
$0.97
$7.49
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.92 | 15.50M | 2.90M | 87.91M | -26.93M | 15.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MyChesCo
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
COVID drug tested in Paxlovid-ineligible patients as monthly flu pill advances - stocktitan.net
Traws targets stockpile nod as COVID drug outperforms Paxlovid in trial - MSN
Wall Street Recap: Can Traws Pharma Inc outperform under higher oil prices2025 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors - TipRanks
Traws Targets Stockpile Nod as COVID Drug Outperforms Paxlovid in Trial - MyChesCo
Can Traws Pharma Inc. grow without dilutionOptions Play & Advanced Swing Trade Entry Alerts - bollywoodhelpline.com
Published on: 2026-01-17 06:20:37 - baoquankhu1.vn
Traws Pharma files IND for influenza treatment, updates COVID drug trial - Investing.com Nigeria
Breakout Zone: How Traws Pharma Inc stock compares to market leadersPrice Action & Risk Controlled Swing Alerts - Bộ Nội Vụ
Traws Pharma files IND for influenza treatment, updates COVID drug trial By Investing.com - Investing.com India
Traws Pharma advances flu and COVID-19 antiviral pipeline - TipRanks
Traws Pharma Files IND for Tivoxavir Marboxil and Updates Ratutrelvir Study - TradingView
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewswire
Published on: 2026-01-11 07:18:09 - ulpravda.ru
New COVID pill shows promise against Paxlovid in early head-to-head trial - MSN
Fed Meeting: Is Traws Pharma Inc. stock a buy before product launches2025 Market WrapUp & Weekly Market Pulse Updates - Улправда
How resilient is Traws Pharma Inc. stock in market downturnsTrade Exit Report & Short-Term Trading Alerts - Улправда
Why Traws Pharma Inc. stock remains on watchlists2025 Market Outlook & Consistent Profit Trade Alerts - ulpravda.ru
Is Traws Pharma Inc. stock cheap at current valuationMarket Activity Report & Community Trade Idea Sharing - Улправда
How Traws Pharma Inc. stock compares to industry benchmarksPortfolio Risk Report & High Accuracy Trade Signal Alerts - Улправда
Traws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call Transcript - MSN
Comparing Miravant Medical Technologies (OTCMKTS:MRVT) and Traws Pharma (NASDAQ:TRAW) - Defense World
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances - MSN
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors - Moscow-Pullman Daily News
Traws Pharma (NASDAQ:TRAW) Shares Down 3.5% – Time to Sell? - Defense World
How Traws Pharma Inc. stock compares to growth peersTechnical Resistance Breaks & Fast Growing Capital Gains - bollywoodhelpline.com
CLARKE TRAFFORD Insider Trades - Nasdaq
Why Traws Pharma Inc. (0T20) stock stays on top picksAnalyst Upgrades & Master Stock Selection - Bollywood Helpline
New COVID Pill Shows Promise Against Paxlovid in Early Head-to-Head Trial - MyChesCo
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Is Traws Pharma Inc a good long term investmentRetail Trading Trends & High Return Wealth Building - earlytimes.in
Momentum Shift: Will Traws Pharma Inc. (0T20) stock benefit from mergersMarket Sentiment Report & Real-Time Buy Zone Alerts - Улправда
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir - MSN
How Traws Pharma Inc. stock performs during Fed tightening cyclesJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - Улправда
How Traws Pharma Inc. stock reacts to global recession fears2025 Growth vs Value & AI Driven Stock Reports - Улправда
Why Traws Pharma Inc. (0T20) stock stays on buy lists2025 Biggest Moves & Consistent Profit Trading Strategies - DonanımHaber
Aug Momentum: How Traws Pharma Inc. stock reacts to global recession fearsWeekly Investment Recap & Free Technical Confirmation Trade Alerts - Улправда
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):